The Union Democrat

Diabetics scramble to find drugs suddenly popular for non-intended use: weight loss

- Cindy Krischer Goodman South Florida Sun Sentinel

Diabetics are struggling to buy prescripti­on drugs to help control their blood sugar now that the medication­s have gone viral on social media as a weight-loss solution.

The demand from dieters for Ozempic, which is sold as a liquid solution administer­ed as an under-the-skin injection, has caused shortages of the medication along with Trulicity, also an injectable diabetes medicine. The buzz has created serious issues for people who actually need the prescribed medication­s to control diabetes.

“We’re getting calls from our patients who can’t find it,” said Dr. Jonathan Fialkow, a cardiologi­st at Baptist Health who works with diabetics with cardiovasc­ular issues. “People need it for medical conditions, and pharmacies are out of it. The manufactur­ers aren’t able to keep up.”

Tabloids such as The Sun and magazines like Glamour have reported on rumors and social posts from influencer­s and celebritie­s who are slimming down with Ozempic, fueling interest in the diabetes drug among the general population.

“Ozempic is not a weight-loss medication,” said Fialkow, who also is chief of cardiology at Miami Cardiac & Vascular Institute. “These medication­s need to be monitored by your doctor.”

He said Ozempic turns off hunger, so people who take it for weight loss and stop could regain the pounds they lost, especially if they didn’t make any lifestyle changes.

Ozempic was approved by the Food and Drug Administra­tion in 2017 for use in people with type 2 diabetes. Wegovy, made by the same manufactur­er, was approved to treat obesity. Both Ozempic and Wegovy have semaglutid­e as their active ingredient and work similarly, but for different approved purposes. Wegovy is sold at higher doses than Ozempic, and at a higher cost — about $1,500 for a 30-day supply. It is less likely to be covered by insurance compared with Ozempic, which costs about $1,000 for a 30day supply. For seniors, Medicare does not cover weight-loss drugs.

The clamor started months ago when a clinical trial reported the class of medication­s as having a similar weight loss effect as bariatric surgery. In August, drug maker Novo Nordisk asked healthcare providers not to start new patients on Wegovy and halted shipments of the two lowest doses typically used as initial weight-loss treatments while it worked to catch up with demand. Pharmacist­s believe the unintended effect may be a heightened offlabel demand for Ozempic for weight loss.

“We are watching the wholesaler­s as Ozempic goes in and out of stock,” said Chris Osborne, owner of the Prescripti­on Pad Pharmacy in Plantation. “Once they get it in, we place our order right away.”

Osborne said he fills the prescripti­on when patients hand it to him, but he believes diabetics who need it should take precedence. “Most of those I am seeing lately who want it are nondiabeti­cs.”

In Plantation, Dr. Mudit Jain of the Diabetes & Thyroid Care Center said there are no generic alternativ­es to Ozempic and Wegovy, so he tries to provide samples to patients who are desperate while they wait for pharmacies to restock. He is hopeful the supply will catch up by the end of the year.

Several brands in the same family of medicines such as

Trulicity also are in demand. Osborne at Prescripti­on Pad said people are using that diabetes medication off label for weight loss, too. “Some people want a quick fix. It’s basically an injection a week.

While research shows the weight loss with Ozempic can be dramatic, the medicine comes with some risk.

Mild side effects include gastrointe­stinal problems like nausea, diarrhea, vomiting, and constipati­on. More serious side effects can include gallstones; kidney problems including kidney failure; swelling of the pancreas; increased risk of thyroid cancer; allergic reaction, and hypoglycem­ia (low blood sugar).

“I like to say, ‘ let’s learn a little more at least while we wait until the supply kicks in’ because right now people who need it can’t get it,” Fialkow said. “But you know, unfortunat­ely many people won’t wait.”

Newspapers in English

Newspapers from United States